Hims & Hers Health on Wednesday said it will offer five formulations of peptides and longevity treatments compounded in the U.S. as part of the initial rollout of its Peptides+ platform, all of which are not approved by regulators. Even as it announced the new products, Hims & Hers acknowledged it has more to learn about how best to use the peptides and how effective they are — underscoring the uncertainty surrounding the growing space. The new offerings come after the federal government eased restrictions on compounding certain unapproved peptides, which are short chains of amino acids.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.
